Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled study of NVA237 in COPD
2008-008394-63Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Mean trough FEV1 at week 12. Started Jul 2009; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-008394-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008394-63.